Department of Commerce, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
JBI Evid Synth. 2024 Sep 1;22(9):1886-1897. doi: 10.11124/JBIES-23-00246.
This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low- and middle-income countries.
RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date.
This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low- and middle-income countries.
The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI's Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use.
PROSPERO CRD42023425850.
本综述将综合研究风湿性心脏病（RHD）在中低收入国家的成本、这些成本的影响以及治疗的成本效益。
由于其临床复杂性、手术治疗和延长的住院时间，RHD 会产生高昂的成本。因此，该疾病对卫生系统、患者及其家庭具有重大的经济影响。迄今为止，尚未发表关于 RHD 治疗经济证据的系统评价。
本综述将考虑所有关于中低收入国家儿童和青年（5-30 岁）RHD 治疗的成本和成本效益研究。
本综述将遵循 JBI 对经济评估证据的系统评价方法。搜索策略将定位英文发表和未发表的研究。将在 MEDLINE（PubMed）、MEDLINE（Ovid）、Embase（Ovid）、Scopus、CINAHL（EBSCOhost）、英国国家卫生服务经济评估数据库、儿科经济数据库评估和成本效益分析登记处进行系统搜索。两名独立评审员将筛选标题和摘要，然后根据纳入标准进行全文审查。将使用修改后的 JBI 经济评估数据提取表提取数据。JBI 的经济评估主导性排名矩阵将用于总结和比较成本和成本效益研究的结果。将使用推荐评估、发展和评估（GRADE）方法来评估与资源利用相关的结果的经济证据的确定性。
PROSPERO CRD42023425850。
